• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by iTeos Therapeutics Inc.

    8/29/25 4:16:59 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ITOS alert in real time by email
    POS AM 1 ny20052905x6_posam.htm POS AM
    As filed with the Securities and Exchange Commission on August 29, 2025

    Registration No. 333-271793
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-271793

    FORM S-3
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     

    ITEOS THERAPEUTICS, INC.
    (Exact Name of Registrant as Specified in Its Charter)
     

         
    Delaware
     
    84-3365066
    (State or Other Jurisdiction of
    Incorporation or Organization)
     
    (IRS Employer
    Identification No.)

    321 Arsenal Street
    Watertown, Massachusetts 02472
    (Address of Principal Executive Offices, including Zip Code)

    Michael Hearne
    Chief Financial Officer
    iTeos Therapeutics, Inc.
    4747 Executive Drive, Suite 210
    San Diego, California 92121
    (858) 281-5372
    (Name, Address and Telephone Number, including Area Code, of Agent for Service)

    Copies to:

    Ryan A. Murr
    Gibson, Dunn & Crutcher LLP
    One Embarcadero Center Suite 2600
    San Francisco, California 94111
    (415) 393-8200

    William Michener
    Nicholas Roper
    Ropes & Gray LLP
    800 Boylston Street
    Boston, MA 02199
    (617) 951-7000
    (Name, address, and telephone number, including area code, of agent for service)
     
    Approximate date of commencement of proposed sale to the public: Not applicable.
    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  ☐
    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.  ☒
    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐
    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 431(b) under the Securities Act, check the following box.  ☐
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
     
    Large accelerated filer
     
    ☐
      
    Accelerated filer
     
    ☐
    Non-accelerated filer
     
    ☒
      
    Smaller reporting company
     
    ☒
           
    Emerging growth company
     
    ☒
     



    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment (the “Post-Effective Amendment”) filed by iTeos Therapeutics, Inc., a Delaware corporation (the “Registrant”), relates to the following Registration Statement on Form S-3 (the “Registration Statement”):

    1.
    Registration Statement No. 333-271793, registering: (i) a base prospectus, which covers the offering, issuance and sale by the Registrant of the Registrant’s common stock, preferred stock, warrants and/or units from time to time in one or more offerings with a total value of up to $300,000,000; and (ii) the sale of up to $125,000,000 of common stock offered by the Registrant under a sales agreement with Cowen and Company, LLC, which was filed with the Securities and Exchange Commission on May 10, 2023.

    On July 18, 2025, the Registrant entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), and Concentra Merger Sub VIII, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, on August 29, 2025, Merger Sub was merged with and into the Registrant with the Registrant surviving as a wholly owned subsidiary of Parent (the “Merger”). In the Merger, each share of Common Stock (the “Shares”) (other than (i) Shares owned or held in the Company’s treasury immediately prior to the Effective Time, (ii) Shares owned directly or indirectly by Parent or Merger Sub immediately prior to the Effective Time and (iii) Shares held by any stockholder of the Registrant who properly exercised appraisal rights under Delaware law) was converted into the right to receive (i) $10.047 per Share in cash and (ii) one non-transferable contractual contingent value right for each Share.

    As a result of the Merger, the Registrant has terminated all offerings of its securities pursuant to the Registration Statement. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all such securities registered under the Registration Statement that remain unsold as of the date hereof and terminates the effectiveness of the Registration Statement.


    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Post-Effective Amendment to the Registration Statement and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on August 29, 2025. No other person is required to sign this Post-Effective Amendment to the Registration Statement in reliance on Rule 478 of the Securities Act of 1933, as amended.

         
     
    ITEOS THERAPEUTICS, INC.
     
     
     
     
    By: /s/ Michael Hearne
     
     
    Name: Michael Hearne
    Title: Chief Financial Officer
     
     

    Get the next $ITOS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ITOS

    DatePrice TargetRatingAnalyst
    5/28/2025$12.00Overweight → Equal Weight
    Wells Fargo
    5/28/2025$12.00Outperform → Neutral
    Wedbush
    5/14/2025$9.00Outperform → Market Perform
    Leerink Partners
    5/14/2025Buy → Neutral
    H.C. Wainwright
    5/13/2025Overweight → Neutral
    Analyst
    8/13/2024$31.00Overweight
    Wells Fargo
    12/13/2021$37.00 → $54.00Buy
    HC Wainwright & Co.
    11/12/2021$55.00 → $54.00Outperform
    SVB Leerink
    More analyst ratings

    $ITOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

    WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (NASDAQ:ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire iTeos for $10.047 in cash per share of iTeos common stock par value $0.001 per share ("iTeos Common Stock"), plus one non-transferable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing (such cash

    7/21/25 7:29:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Therapeutics Announces Its Intention to Wind Down Operations

    - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1 WATERTOWN, Mass. and GOSSELIES, Belgium, May 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the intention to wind down its operations as part of a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Following a thorough

    5/28/25 8:30:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

    – GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported topline results from an updated interim analysis of GALAXIES Lung-201, the Phase 2 platform s

    5/13/25 7:55:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Call Matthew closing all direct ownership in the company (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    8/29/25 4:30:31 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Detheux Michel closing all direct ownership in the company (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    8/29/25 4:30:29 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Lee David K

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    8/29/25 4:30:26 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iTeos Therapeutics downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded iTeos Therapeutics from Overweight to Equal Weight and set a new price target of $12.00

    5/28/25 10:52:33 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Therapeutics downgraded by Wedbush with a new price target

    Wedbush downgraded iTeos Therapeutics from Outperform to Neutral and set a new price target of $12.00

    5/28/25 10:12:02 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded iTeos Therapeutics from Outperform to Market Perform and set a new price target of $9.00

    5/14/25 8:56:56 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    SEC Filings

    View All

    SEC Form 15-12G filed by iTeos Therapeutics Inc.

    15-12G - iTeos Therapeutics, Inc. (0001808865) (Filer)

    9/8/25 4:15:45 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by iTeos Therapeutics Inc.

    EFFECT - iTeos Therapeutics, Inc. (0001808865) (Filer)

    9/5/25 12:15:04 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by iTeos Therapeutics Inc.

    SCHEDULE 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

    9/3/25 4:15:17 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ecor1 Capital, Llc bought $38,685,562 worth of shares (4,958,978 units at $7.80) (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    5/16/25 6:52:07 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Gall Matthew bought $38,635 worth of shares (5,000 units at $7.73), increasing direct ownership by 8% to 65,429 units (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    11/19/24 7:59:14 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gall Matthew bought $41,850 worth of shares (5,000 units at $8.37), increasing direct ownership by 35% to 19,429 units (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    10/12/23 5:09:33 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Leadership Updates

    Live Leadership Updates

    View All

    iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

    WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) --  iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies. "As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we're excited to welcome Dr. Feltquate as Chief Medical Officer," said Michel Detheux, Ph.D., presi

    8/5/24 7:00:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

    WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company's audit committee. "Expanding our board with industry leaders and oncology veterans with commercial, scientific, and corporate portfolio strategy experience is of the utmost importance for iTeos. After the recent appointment of Servier's David Lee, we are thrilled to welcome Jill DeSimone to o

    3/6/24 7:01:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

    - Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Completed enrollment of third dose cohort in Phase 1 trial of EOS-984- Preclinical presentations on role of ENT1 at SITC Spring Scientific and profile of EOS-984 at AACR annual meeting- Cash and investment balance of $632.7 million as of December 31, 2023 expected to provide runway through 2026 across a number of impactful portfolio milestones- Oncology veterans Jill DeSimone and David K. Lee to join Board of Directors WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NA

    3/6/24 7:00:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Financials

    Live finance-specific insights

    View All

    iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

    - Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting- iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 14, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stag

    9/14/24 2:30:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

    - First patients dosed in clinical trial of anti-TIGIT monoclonal antibody, EOS-448, in combination with pembrolizumab and with inupadenant in patients with solid tumors - Advanced clinical development of inupadenant, EOS-850, an A2A receptor antagonist, with initiation of an expansion in PD-1 resistant melanoma in combination with pembrolizumab as well as a planned study further exploring novel predictive biomarkers - Received full upfront payment of $625MM at closing of development and commercialization collaboration agreement with GSK for EOS-448 - Cash balance of $899.8MM as of September 30, 2021, providing runway into 2026 to support clinical development plans for EOS-448 and inupad

    11/10/21 4:01:00 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, November 10, 2021 to report its third quarter 2021 financial results and provide a corporate update. To access the live conference call, please dial 833-927-1758 (domestic) or 929-526-1599 (international) and refer to conference access code 861337. A live audio webcast of the event will also be accessible from

    11/3/21 7:00:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by iTeos Therapeutics Inc.

    SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/21/24 8:27:38 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by iTeos Therapeutics Inc.

    SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/19/24 9:57:32 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by iTeos Therapeutics Inc.

    SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/18/24 9:57:13 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care